Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 30, 2023

Dabrafenib Plus Trametinib in Patients With BRAFV600E-Mutated Rare Cancers

Nature Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Nat. Med. 2023 Apr 14;[EPub Ahead of Print], V Subbiah, RJ Kreitman, ZA Wainberg, A Gazzah, U Lassen, A Stein, PY Wen, S Dietrich, MJA de Jonge, JY Blay, A Italiano, K Yonemori, DC Cho, FYFL de Vos, P Moreau, EE Fernandez, JHM Schellens, CC Zielinski, S Redhu, A Boran, VQ Passos, P Ilankumaran, YJ Bang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading